KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-α production
- 18 July 1997
- journal article
- Published by Elsevier BV in Life Sciences
- Vol. 61 (8), 795-803
- https://doi.org/10.1016/s0024-3205(97)00561-4
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- The expression of TNF alpha by human muscle. Relationship to insulin resistance.JCI Insight, 1996
- Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.JCI Insight, 1995
- Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha.JCI Insight, 1994
- Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitorNature, 1994
- Processing of tumour necrosis factor-α precursor by metalloproteinasesNature, 1994
- Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processingNature, 1994
- Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistanceEndocrinology, 1994
- Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin ResistanceScience, 1993
- Serum tumour necrosis factor alpha and insulin resistance in gastrointestinal cancerBritish Journal of Surgery, 1992
- Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose outputEndocrinology, 1992